Evidence map›Paper›PMID 38090417›Full record

ReviewCureus2023

A Comprehensive Review on Postmenopausal Osteoporosis in Women.

Samruddhi H Charde, Abhishek Joshi, Juhi Raut

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Beyond the initial impact: a systematic review of post-traumatic bone loss and its mechanisms.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Treatment patterns of romosozumab in postmenopausal women with severe osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Samruddhi H ChardeCommunity Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research (Deemed to be University), Wardha, IND.
Abhishek JoshiCommunity Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research (Deemed to be University), Wardha, IND.
Juhi RautCommunity Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research (Deemed to be University), Wardha, IND.
Jawaharlal Nehru Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In India, a sizeable share of the female population is in the postmenopausal or perimenopausal stage. Issues related to aging in women are an increased risk of broken bones, a decrease in cortical and cancellous bone thickness, and a decrease in bone mineral density (BMD). Osteoporosis has a severely detrimental effect on the life of women, lowering their standard of living, decreasing the quality of their lives, and increasing their likelihood of fractures. It can be terrible if the fracture affects the hip or the spine since it could leave you immobile. Postmenopausal osteoporosis is related to lack of estrogen and lack of eggs produced by ovaries seen with increasing age. After many years of study, the role of estrogen is now well established in bone remodelling. Estrogen contributes to the resorption and strengthening of bone. It detects less density of bone at specific site and helps in strengthening the bone at that location. Treatment choices are based on severity, rate of advancement, and individual patient-specific characteristics. By adopting a lifecycle approach, all women should be educated about this illness and inspired to adopt a healthy lifestyle that includes regular exercise and a balanced diet. All premenopausal women should be advised to take vitamin D and calcium supplements regardless of whether or not they have any bone defects. Smoking and alcohol consumption should also be restricted. Pharmacological intervention is carried out on patients diagnosed with the disease. Drugs should be chosen based on their side effects and contradictions. It's crucial to do follow-up, and patient compliance should be closely observed. This article raises awareness of this widespread illness and helps women of postmenopausal age take the required precautions to stop bone thinning and manage its progress; moreover, it also reviews the literature already published on it.

Indexed as

bonelifestylemanagementosteoporosispostmenopause

Identifiers

PMID38090417
PMCPMC10711335
OpenAlexW4388550995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.